XM does not provide services to residents of the United States of America.
C
C

CarlZeiss

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

ASMI, EasyJet, Kooth

EUROPE RESEARCH ROUNDUP-ASMI, EasyJet, Kooth July 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including ASMI, EasyJet and Kooth, on Wednesday. HIGHLIGHTS * ASMI ASMI.AS : Jefferies raises target price to EUR 880 from EUR 780 * B.P. Marsh & Partners Plc BPM.L : Jefferies raises target price to 625p from 560p * EasyJet EZJ.L : JP Morgan cuts target price to 640p from 670p * Kooth Plc KOO.L : Berenberg initiates coverage with buy rating;
3
A
A
A
A
B
B
C
C
C
D
D
E
E
E
F
K
A
H
A
A
D

Hochtief, Telenor, Zalando SE

EUROPE RESEARCH ROUNDUP-Hochtief, Telenor, Zalando SE June 24 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Hochtief AG, Telenor and Zalando SE, on Monday. HIGHLIGHTS * Associated British Foods ABF.L : HSBC raises target price to 3,075p from 3,010p * Berkeley Group Holdings Plc BKGH.L : Morgan Stanley cuts PT to 4,369p from 4,516p * Hochtief AG HOTG.DE : Jefferies raises target price to EUR 124 from EUR 109 * Telenor TEL.OL : HSB
A
A
A
A
B
B
C
D
D
E
E
E
E
H
H
I
I
K
L
M
M
O
S
T
T
U
V
Z
A
A
A
B
F
L
R
S
S

Givaudan, National Grid, Schneider Electric

EUROPE RESEARCH ROUNDUP-Givaudan, National Grid, Schneider Electric June 18 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Givaudan, National Grid and Schneider Electric, on Tuesday. HIGHLIGHTS * Crest Nicholson Holdings Plc CRST.L : RBC raises target price to 250p from 175p * Givaudan SA GIVN.S : JP Morgan raises target price to CHF 4,200 from CHF 3,800 * National Grid NG.L : Barclays cuts target price to 1120p from 1365p * Schne
A
B
C
C
E
G
G
H
H
H
I
I
L
L
N
P
S
S
S
H
A
A
N
S
S
W

Carl Zeiss Meditec Cuts FY 23/24 Outlook Revenue And EBIT

BRIEF-Carl Zeiss Meditec Cuts FY 23/24 Outlook Revenue And EBIT June 17 (Reuters) - CARL ZEISS MEDITEC AG AFXG.DE : REVENUE AND EBIT FORECAST FOR FISCAL YEAR 2023/24 REDUCED AMID SLOWER THAN EXPECTED RECOVERY OF EQUIPMENT BUSINESS IN COMBINED MONTHS OF APRIL AND MAY 2024, ORDER ENTRY, REVENUE AND EBIT CONTINUED TO FALL SHORT OF PREVIOUS YEAR'S LEVE
C

JPM puts Carl Zeiss on negative Catalyst Watch on downside risks to earnings

BUZZ-JPM puts Carl Zeiss on negative Catalyst Watch on downside risks to earnings ** J.P.Morgan places Carl Zeiss Meditec AFXG.DE on negative Catalyst Watch, citing downside risks to 2024 guidance and 2025 consensus ** The German medical technology firm's stock is down 2.85% ** JPM says a cut to 2024 outlook (potentially at Q3) is "well flagged" al
C
J

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.